English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduOn March 8, the U.S. Food and Drug Administration approved a new indication for the use of semaglutide (brand Wegovy) to “reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or…
Tag: semaglutide
Obesity drugs and mental health: UTSW expert says GLP-1s may exacerbate problems for some patients
New weight-loss drugs have helped people with their diabetes, obesity, even high blood pressure. But how they affect our mental health is a much more complicated issue, says Dr. Carrie McAdams, a psychiatrist and eating disorders expert at UT Southwestern…
Physician Dispels Myths and Shares Insight Ahead of American Diabetes Month
More than 37 million Americans have been diagnosed with diabetes, with another 8.5 million believed to be living with the condition undiagnosed. In addition, 38 percent of the United States adult population is estimated to have prediabetes, a serious condition…
Phase II Trial Studies Effects of Semaglutide Medication in Patients with NASH
Nonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis…
Three Kidney Transplants, Weight Gain and a Journey Back to Wellness
Rowena Roque, 46, was having a problem that many people can relate to: doing everything in her power to lose weight and get healthy but never succeeding.